WASHINGTON—President Donald Trump announced a deal to bring state Medicaid programs access to most-favored-nation pricing on new Regeneron drugs, marking the 17th deal he has struck with a major pharmaceutical company since the fall.
According to a White House fact sheet, the deal also ensures that other countries cannot “use price controls to freeride on American innovation by guaranteeing MFN prices on all new innovative medicines Regeneron brings to market.”
“The agreement requires Regeneron to repatriate increased foreign revenue on existing products that Regeneron realizes as a result of the President’s strong America First U.S. trade policies for the benefit of American patients,” the White House adds.
Under the agreement, the price of Regeneron’s Praluent, a cholesterol medicine, will drop to $225 from $537 when purchased through the TrumpRx website, according to the administration.
Trump touted the deal in the Oval Office, flanked by Centers for Medicare & Medicaid Services Administrator
Continue reading
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!